Shares of NovoCure Ltd. (NASDAQ:NVCR) dropped 2.2% during mid-day trading on Monday . The stock traded as low as $7.54 and last traded at $7.65, with a volume of 103,074 shares trading hands. The stock had previously closed at $7.82.

NVCR has been the subject of several analyst reports. Wedbush dropped their target price on NovoCure from $30.00 to $20.00 and set an “outperform” rating for the company in a report on Friday, July 29th. Zacks Investment Research cut NovoCure from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. JMP Securities dropped their target price on NovoCure from $43.00 to $34.00 and set a “market outperform” rating for the company in a report on Friday, July 29th. JPMorgan Chase & Co. dropped their target price on NovoCure from $29.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, July 29th. Finally, Barclays PLC dropped their target price on NovoCure from $12.00 to $9.00 and set an “underweight” rating for the company in a report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. NovoCure presently has a consensus rating of “Hold” and an average target price of $21.43.

The firm’s market capitalization is $660.46 million. The firm has a 50-day moving average price of $9.35 and a 200-day moving average price of $11.81.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Thursday, July 28th. The company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.11. The firm earned $17.90 million during the quarter, compared to analyst estimates of $15.90 million. On average, equities analysts predict that NovoCure Ltd. will post ($1.74) earnings per share for the current year.

In other news, COO Michael J. Ambrogi sold 20,000 shares of NovoCure stock in a transaction on Wednesday, June 8th. The stock was sold at an average price of $12.24, for a total value of $244,800.00. Following the completion of the sale, the chief operating officer now owns 324,084 shares of the company’s stock, valued at $3,966,788.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gert L. Perlhagen sold 676,576 shares of NovoCure stock in a transaction on Friday, August 5th. The shares were sold at an average price of $1.85, for a total value of $1,251,665.60. Following the completion of the sale, the director now directly owns 676,576 shares of the company’s stock, valued at approximately $1,251,665.60. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.